Benefits found with the AlbuHEP Branched Chain Amino Acid (BCAA) formula

  • Improvement in serum albumin in patient with decompensated hepatic cirrhosis with a pre-treatment albumin level of 3.5g/dL or less despite adequate dietary intake.
  • Improvement in Event-free survival (specifics described below)
  • Improvement in rate of hepatic failure
  • Improvement in general health perception

Improvement in serum albumin

Improvement in event free survival

Plese see the full publication linked below for more detailed information. In summary patients with the following characteristics saw largest benefit in survival.

  • Those < 65yo
  • Those with HCV related cirrhosis
  • Females
  • Those with a BTR <4.0

Improvement in hepatic failure

Proportion of patients without aggravation of Hepatic Failure including: ascites, peripheral edema, hepatic encephalopathy, jaundice

Improvement in general health perception

Wholesale access to AlbuHEP

Please contact your wholesale partner if you would like access to AlbuHEP from the wholesale distribution channels which you pull from.

Dosing AlbuHEP

The standard dose is one scoop containing 4g of BCCAs, three times daily with or after meals.

Patients not appropriate the treat with AlbuHEP

  • Patients with congenital BCAA metabolic abnormality such as MSUD.
  • Patients with stage 3 or 4 coma due to hepatic encephalopathy.
  • Patient with a total bilirubin level of 3 mg/dL or more.
  • Patients with a severely depressed hepatic function for protein synthesis.

How do patients get AlbuHEP for outpatient use

Currently the only way to get AlbuHEP is directly on this site. We do not distribute via Amazon due to the high levels of fees, fraud an theft that occurs on that platform.

BCAAs and ingredients in AlbuHEP

In decending order:

  • L-Leucine
  • L-Valine
  • L-Isoleucine
  • Natural and Aritificial Flavors
  • L-Malic Acid
  • Calcium Silicate
  • Sunflower Lecithin
  • Sucralose
  • Acesulfame K

Patients not appropriate to treat with AlbuHEP

  • Patients with congenital BCAA metabolic abnormality such as MSUD.
  • Patients with stage 3 or 4 coma due to hepatic encephalopathy.
  • Patient with a total bilirubin level of 3 mg/dL or more.
  • Patients with a severely depressed hepatic function for protein synthesis.

Precautions when prescribing AlbuHEP

AlbuHEP is indicated for patients presenting with hypoalbuminemia despite adequate dietary intake or in whom total dietary calories and protein (amino acids) intake is restricted due to complicated diabetes mellitus or hepatic encephalopathy, among patients with decompensated hepatic cirrhosis presenting with hypoalbuminemia as indicated by a serum albumin level of 3.5 g/dL or less with current or a history of ascites/edema or hepatic encephalopathy.

Side effects

Side effects seen with the BCAA formulation found in AlbuHEP are as follows:

  • Abdominal Distension: 2.1%
  • diarrhea: 1.2%
  • Constipation: 1.0%
  • Hyperammonemia: 0.8%

Penguin Medical manufactures and distributes AlbuHEP. HepLOLA for Hepatic Encephalopathy, also from Penguin Medical has been trusted by Hospitals and Health care providers for over 5 years.

Interactions with drugs

The interaction of AlbuHEP has not been studied and therefore interactions are not know.